The efficacy of pro- and anticoagulant therapy in plasma from patients with liver cirrhosis .
Completed
- Conditions
- coagulation.hemostasis10064477
- Registration Number
- NL-OMON37417
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 126
Inclusion Criteria
Inclusion criteria study group:
- Cirrhosis
- >18 year
- Signed informed consent
Inclusion criteria healhty control group
- >18 year
- Signed informed consent
Exclusion Criteria
Exclusion criteria study group:
- Congenital coagulation disorder
- Active infection
- Acute liver failure
- Use of anticoagulant drugs in the past 10 days
- Pregnancy
- HIV+
- (<7 days) transfusion with blood products;Exclusion criteria control-group
- Documented history of congenital coagulation disorder
- History of vascular disease
- History of hepatic disease
- History of any systemic disease
- Recent viral infection (>2 weeks)
- Use of anticoagulant drugs in the past 10 days
- Pregnancy
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The functionality of the secondary hemostatic system, as determined by thrombin<br /><br>generation assays.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable</p><br>